EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical characteristics, treatment, and treatment switch after molecular‐genetic classification in individuals with maturity‐onset diabetes of the young: Insights from the multicenter real‐world DPV registry

Stefanie Lanzinger iD, Katharina Laubner, Katharina Warncke, Julia K Mader, Sebastian Kummer, Claudia Boettcher, Torben Biester, Angela Galler, Daniela Klose, Reinhard W Holl

Journal of Diabetes · 2024

DOI: 10.1111/1753-0407.70028 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Diabetes, 2024. Verfasst von Stefanie Lanzinger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Epidemiology and Medical Biometry, CAQM, Ulm University, Ulm, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Registries, Hypoglycemic Agents, Hepatocyte Nuclear Factor 1-alpha. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: REDDIE project, Robert Koch Institut, German Center for Diabetes Research (DZD).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Individuals with maturity‐onset diabetes of the young (MODY) are often misdiagnosed as type 1 or type 2 diabetes and receive inappropriate care. We aimed to investigate the characteristics and treatment of all MODY types in a multicenter, real‐world setting.

Methods

Individuals with MODY from the diabetes prospective follow‐up (DPV) registry were studied. We compared clinical parameters during the first year of diabetes and the most recent treatment year after MODY diagnosis.

Results

A total of 1640 individuals were identified with GCK ‐MODY ( n = 941) and HNF1A ‐MODY ( n = 417) as the most frequent types. Among these, 912 individuals were available with information during the first and the most recent treatment year (median duration of follow‐up: 4.2 years [2.6–6.6]). Positive beta cell autoantibodies were present in 20.6% (15.2% IAA). Median age at diagnosis ranged from 9.9 years in GCK ‐MODY (Q1–Q3: 6.2–13.1 years) and INS ‐MODY (2.7–13.7 years) to 14.3 years (5.0–17.1) in KCNJ11 ‐MODY. Frequency of oral antidiabetic agents (OAD) use increased and insulin decreased in HNF4A ‐MODY (OAD: 18% to 39%, insulin: 34% to 23%) and in HNF1A ‐MODY (OAD: 18% to 31%, insulin: 35% to 25%). ABCC8 ‐MODY was characterized by a decrement in nonpharmacological treatment (26% to 16%) and “insulin only” treatment (53% to 42%), while the proportion of individuals treated with OAD but no insulin increased from 0% to 21%.

Conclusions

Our results indicate that some teams caring for individuals with MODY are hesitant with regard to current recommendations. Registries are an essential source of information and provide a basis for discussing treatment guidelines for MODY. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2RegistriesHypoglycemic AgentsHepatocyte Nuclear Factor 1-alphaHumansMaleFemaleAdolescentChildProspective StudiesFollow-Up StudiesGerminal Center KinasesPotassium Channels, Inwardly RectifyingSulfonylurea ReceptorsInsulinHepatocyte Nuclear Factor 4

Stichwörter der Autor:innen

MODYdiabetes prospective follow‐up (DPV) registrymonogenic diabetesoral antidiabetic drugsreal‐world data

Substanzen

Hypoglycemic AgentsHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanGerminal Center KinasesPotassium Channels, Inwardly RectifyingABCC8 protein, humanSulfonylurea ReceptorsInsulinMAP4K2 protein, humanHepatocyte Nuclear Factor 4

Autor:innen und Institutionen

  • Institute of Epidemiology and Medical Biometry, CAQM, Ulm University, Ulm, Germany.
  • Munich-Neuherberg, German Center for Diabetes Research (DZD), Munich, Germany.
  • Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
  • Department of Pediatrics, Kinderklinik München Schwabing, Technical University of Munich School of Medicine, Munich, Germany.
  • Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

ORCID-Profile: Stefanie Lanzinger

Förderung

  • REDDIE project
  • Robert Koch Institut
  • German Center for Diabetes Research (DZD)

Zitieren

APA

Lanzinger, S., Laubner, K., Warncke, K., Mader, J. K., Kummer, S., Boettcher, C., Biester, T., Galler, A., Klose, D., & Holl, R. W. (2024). Clinical characteristics, treatment, and treatment switch after molecular‐genetic classification in individuals with maturity‐onset diabetes of the young: Insights from the multicenter real‐world DPV registry. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70028

Vancouver

Lanzinger S, Laubner K, Warncke K, Mader JK, Kummer S, Boettcher C, et al. Clinical characteristics, treatment, and treatment switch after molecular‐genetic classification in individuals with maturity‐onset diabetes of the young: Insights from the multicenter real‐world DPV registry. Journal of Diabetes. 2024. doi:10.1111/1753-0407.70028

BibTeX
@article{Lanzinger2024,
  author = {Lanzinger, Stefanie and Laubner, Katharina and Warncke, Katharina and Mader, Julia K and Kummer, Sebastian and Boettcher, Claudia and Biester, Torben and Galler, Angela and Klose, Daniela and Holl, Reinhard W},
  title = {Clinical characteristics, treatment, and treatment switch after molecular‐genetic classification in individuals with maturity‐onset diabetes of the young: Insights from the multicenter real‐world DPV registry},
  journal = {Journal of Diabetes},
  year = {2024},
  doi = {10.1111/1753-0407.70028}
}
Kostenlos starten →